Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis

Tuberculosis Clinical Trial

Official title:

Impact of a Package of Intensive Smoking-cessation Interventions Versus Smoking-cessation Advice on Outcomes in Smear-positive Patients With Pulmonary Tuberculosis; a Randomised Controlled Trial (STB_RCT).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01517022
• Other study ID #: SKS/Med/NI1161
• Status: Completed
• Phase: Phase 3
• First received: June 23, 2011
• Last updated: October 12, 2017
• Start date: November 2010
• Est. completion date: September 2016

Study information

• Verified date: October 2017
• Source: All India Institute of Medical Sciences, New Delhi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to determine the impact of a package of smoking-cessation interventions on a composite measure of Tuberculosis (TB) treatment-related outcomes.

Given the lack of objective clinical data/evidence about the impact of smoking-cessation on TB-related outcomes, yet subjective expert opinion that smoking cessation is highly likely to be beneficial particularly in patients with TB, this study proposes to determine the impact of an intensive package of smoking-cessation interventions aimed to promote smoking-cessation (counseling plus nicotine replacement therapy, NRT), on patient response to anti-tuberculosis therapy. This is to be compared with the structured counselling for smoking-cessation that is recommended to be routinely provided by health care workers to all patients who are smokers. If the results prove that such a smoking-cessation PI indeed improves outcomes in TB patients, such information would strongly motivate for the institution of more intensive smoking-cessation interventions in TB clinics than is currently being employed for TB patients

Description:

No clinical trials have been done to determine if the cessation of smoking has any influence on outcome in tuberculosis patients. In particular, if smoking cessation leads to a higher rate of sputum culture-conversion at 2 months, TB transmission rates should be reduced. Such targeted smoking-cessation intervention may be more successful than general public education strategies in reducing the spread of TB in high-incidence countries Tuberculosis (TB) . The WHO has estimated that approximately a third of the world's population is infected with Mycobacterium tuberculosis, and approximately 2 million die from TB every year. Tobacco smoking, which is the single most preventable cause of death in the world today, appears to be an important risk factor for TB disease and mortality, especially in countries such as India. The smoking-TB association has major public health implications because in many of the developing countries where there is a high prevalence of TB, smoking is also a common practice. Smoking is widespread, with approximately a third of the global population aged 15 years or above being smokers, but has reached epidemic proportions in countries such as India, China and Russia. For example, in India more than half of the rural male population is estimated to smoke and India accounts for 1.85 million TB cases each year. Therefore in India, as for other developing countries, the co-existence of a high TB and smoking burden is a major health concern, and further underscores the importance of promoting smoking cessation to the general public. In India, studies have shown a strong association between tobacco and TB mortality. An estimated third of male TB deaths in India may be due to smoking. However, there is concern that many of the published studies did not adequately control for bias and confounding (that may have caused spurious associations).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 800
• Est. completion date: September 2016
• Est. primary completion date: September 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• any adult (> 18 years)

• Recently diagnosed (primary TB/Relapse TB) smear-positive TB patient who self-reports to smoke at least 10 whole cigarettes or bidis (rolled tobacco leaf) per day, every day

Exclusion Criteria:

• patients will be excluded from recruitment to the study if they fall into any one or more of these exclusion categories:

• Inability to give consent or < 18 years

• Patients who self-report to smoke less than 10 whole cigarettes/bidis per day

• TB patients who have already started anti-tuberculosis therapy for more than 1 week.

• Patients with known multidrug-resistant TB (or XDR) (information provided by patient or the information is available in the clinic folder).

• Known HIV-positive patients

• Contra-indications to NRT (patients with a history of severe cardiovascular disease including arrhythmias, recent myocardial infarction (within the last 6 months), recent cerebrovascular incident (6 months), and/ or history of peripheral vascular disease, phaeochromocytoma, poorly controlled diabetes mellitus, hyperthyroidism, renal/hepatic impairment or gastritis/peptic ulcers). Patients with asthma or depression will also be excluded, as quitting may have an effect on medications used for these conditions. Patients with severe skin disorders (such as psoriasis or eczema) will also be excluded.

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Drug:
• nicotine replacement therapy
nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks

Locations

Country	Name	City	State
India	All India Institute of Medical Sciences, Ansari Nagar	New Delhi

Sponsors (3)

Lead Sponsor	Collaborator
All India Institute of Medical Sciences, New Delhi	Sri Venkateswara Institute of Medical Sciences University, University of Cape Town

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1. Change in TB Score at second month and sixth month	Composite score for objective and subjective improvement measured at baseline, second month and sixth month	Measured at baseline, second month and sixth month.
Primary	Sputum culture conversion	Sputum culture conversion at second month using solid/liquid culture technique	Measured at baseline and second month
Secondary	Sputum smear conversion	Protocol was amended to access sputum conversion weekly up to second month	Measured at baseline, second week, fourth week, second month and sixth months
Secondary	Mortality at sixth month	To determine number of mortality at the end of follow-up	Sixth month
Secondary	More than 10% weight gain at six months	To determine rate of weight gain after completion of treatment	Sixth month
Secondary	Proportion of subjects in each group that have quit smoking at second month	To determine the rate of smoking cessation in the cohort	Sixth month
Secondary	Treatment completion		Six months for new cases and eight months for re-treatment cases following regimen 2
Secondary	Cure, failure and default rate	To determine cure, failure and default rate in the cohort	At sixth month